[Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs].
D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003523:Cycloserine / Q000008:administration & dosage; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000008:administration & dosage; D005000:Ethionamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage; D007612:Kanamycin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D013307:Streptomycin / Q000008:administration & dosage; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014756:Viomycin / Q000008:administration & dosage
D000995:Antitubercular Agents; D007612:Kanamycin; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin; D014756:Viomycin